JAB JOSTLE. Europe’s legal battle with AstraZeneca (AZN.L) may be more about politics than money. The European Commission said on Monday it had launched a legal action against the $138 billion drug giant for not making good on its contract to supply Covid-19 vaccines, and not having a “reliable plan” to ensure delivery read more . AstraZeneca says the claim is without merit. The case may take years and rack up large legal bills. The fact the UK group is selling vaccines at cost, rather than for profit, may weaken Brussels’ case. The move also looks odd given Europe’s increasing preference for mRNA jabs, such as those developed by Pfizer (PFE.N) and BioNTech, for which it is about to secure up to 1.8 billion new doses. Member states are wary of AstraZeneca’s inoculation following cases of blood clots. But with Europe still trailing the United Kingdom and the United States in its vaccine programme, bashing AstraZeneca may keep other drugmakers in line, and show European Union citizens the commission has their back. (By Aimee Donnellan) On Twitter http://twitter.com/breakingviews Earlier in Capital Calls: Honest IPO read more Total pulls legal ripcord in Mozambique read more U.S. bank mergers read more Nestlé reaches for the vitamin pills read more When rebranding turns into Abrdn read more